Carl Zeiss Meditec invests in innovative radiotherapy solution for wet age-related macular degeneration

Downloads and Links
JENA/Germany, 22.12.2014.
Carl Zeiss Meditec Inc., a 100%-owned subsidiary of Carl Zeiss Meditec AG (ISIN: DE0005313704) has signed a collaboration agreement with Oraya Therapeutics Inc., Newark, USA (Oraya). Over the past few years, Oraya has developed the novel low energy radiation therapy "Oraya Therapy" for wet age-related macular degeneration (wet AMD) and introduced it to the market.

Under the terms of the agreement, Carl Zeiss Meditec will provide funding to Oraya for the implementation of its growth strategy over a period of up to two years and in turn receive rights for a participation in the company reaching up to a majority stake after two years. The amount of the funding provided to Oraya has not been disclosed. Carl Zeiss Meditec expects this investment to further strengthen its role as global innovation leader in ophthalmology as well as its existing portfolio of solutions for diagnosis and therapy of eye diseases.

Jann Gerrit Ohlendorf
Director Corporate Communications
Carl Zeiss Meditec AG
Phone: +49 3641 220-331
Fax: +49 3641 220-332
press.meditec@zeiss.com

Sebastian Frericks
Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors.meditec@zeiss.comNumber: 0155-2014-ENG OP

Number of Words: 161
Number of Characters: 1022
distributed by